Higher rates of decline for women and apolipoprotein e ε4 carriers

American Journal of Neuroradiology

Volumn 34, Issue 12, 2013, Pages 2287-2293

  Holland, D ^a   Desikan, R S ^b   Dale, A M ^a,b   McEvoy, L K ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E4; BIOCHEMICAL MARKER; PHOSPHOPROTEIN; TAU PROTEIN;

AGE; AGED; ALZHEIMER DISEASE; AMYGDALOID NUCLEUS; ARTICLE; BRAIN ATROPHY; COHORT ANALYSIS; CONTROLLED STUDY; ENTORHINAL CORTEX; FEMALE; HETEROZYGOTE; HIPPOCAMPUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; ORBITAL CORTEX; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN PHOSPHORYLATION; SEX DIFFERENCE; TEMPORAL LOBE;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; APOLIPOPROTEIN E4; BIOLOGICAL MARKERS; BRAIN; COMORBIDITY; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HETEROZYGOTE; HUMANS; INCIDENCE; MAGNETIC RESONANCE IMAGING; MALE; MILD COGNITIVE IMPAIRMENT; REPRODUCIBILITY OF RESULTS; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SEX DISTRIBUTION; UNITED STATES; WOMEN'S HEALTH;

EID: 84885348644     PISSN: 01956108     EISSN: 1936959X     Source Type: Journal    
DOI: 10.3174/ajnr.A3601     Document Type: Article

References (48)

1. Duker AP, Espay AJ, Wszolek ZK, et al. Atypical motor and behavioral presentations of Alzheimer disease: a case-based approach. Neurologist 2012;18:266-72
2. Murray ME, Graff-Radford NR, Ross OA, et al. Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study. Lancet Neurol 2011;10:785-96
3. Holland D, Desikan RS, Dale AM, et al. Rates of decline in Alzheimer disease decrease with age. PLoS One 2012;7:e42325
4. van der Flier WM, Pijnenburg YA, Fox NC, et al. Early-onset versus late-onset Alzheimer's disease: the case of the missingAPOEvarepsilon4 allele. Lancet Neurol 2011;10:280-88
5. Alzheimer's Association. 2013 Alzheimer's disease facts and figures. Alzheimers Dement 2013;9:208-45
6. Miech RA, Breitner JC, Zandi PP, et al. Incidence of AD may decline in the early 90s for men, later for women: the Cache County study. Neurology 2002;58:209-18
7. Farrer LA, Cupples LA, Haines JL, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: a meta-analysis: APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 1997;278:1349-56
8. Seshadri S, Wolf PA, Beiser A, et al. Lifetime risk of dementia and Alzheimer's disease: the impact of mortality on risk estimates in the Framingham Study. Neurology 1997;49:1498-504
9. Andersen K, Launer LJ, Dewey ME, et al. Gender differences in the incidence of AD and vascular dementia: the EURODEM Studies: EURODEM Incidence Research Group. Neurology 1999;53:1992-97
10. Plassman BL, Langa KM, McCammon RJ, et al. Incidence of dementia and cognitive impairment, not dementia in the United States. Ann Neurol 2011;70:418-26
11. Breitner JC, Wyse BW, Anthony JC, et al. APOE-epsilon4 count predicts age when prevalence ofADincreases, then declines: the Cache County Study. Neurology 1999;53:321-31
12. Barnes LL, Wilson RS, Schneider JA, et al. Gender, cognitive decline, and risk of AD in older persons. Neurology 2003;60:1777-81
13. Hebert LE, Scherr PA, McCann JJ, et al. Is the risk of developing Alzheimer's disease greater for women than for men? Am J Epidemiol 2001;153:132-36
14. Ghebremedhin E, Schultz C, Thal DR, et al. Gender and age modify the association between APOE and AD-related neuropathology. Neurology 2001;56:1696-701
15. Irvine K, Laws KR, Gale TM, et al. Greater cognitive deterioration in women than men with Alzheimer's disease: a meta analysis. J Clin Exp Neuropsychol 2012;34:989-98
16. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993;261:921-23
17. Verghese PB, Castellano JM, Holtzman DM. Apolipoprotein E in Alzheimer's disease and other neurological disorders. Lancet Neurol 2011;10:241-52
18. Sando SB, Melquist S, Cannon A, et al. APOE epsilon 4 lowers age at onset and is a high risk factor for Alzheimer's disease: a case control study from central Norway. BMC Neurol 2008;8:9
19. Khachaturian AS, Corcoran CD, Mayer LS, et al. Apolipoprotein E epsilon4 count affects age at onset of Alzheimer disease, but not lifetime susceptibility: the Cache County Study. Arch Gen Psychiatry 2004;61:518-24
20. Corder EH, Saunders AM, Strittmatter WJ, et al. Apolipoprotein E, survival in Alzheimer's disease patients, and the competing risks of death and Alzheimer's disease. Neurology 1995;45:1323-28
21. Holland D, McEvoy LK, Dale AM. Unbiased comparison of sample size estimates from longitudinal structural measures in ADNI. Hum Brain Mapp 2012;33:2586-602
22. Holland D, Dale AM. Nonlinear registration of longitudinal images and measurement of change in regions of interest. Med Image Anal 2011;15:489-97
23. Holland D, McEvoy LK, Desikan RS, et al. Enrichment and stratification for predementia Alzheimer disease clinical trials. PloS One 2012;7:e47739
24. Arriagada PV, Marzloff K, Hyman BT. Distribution of Alzheimertype pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer's disease. Neurology 1992; 42:1681-88
25. Arnold SE, Hyman BT, Flory J, et al. The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer's disease. Cereb Cortex 1991;1:103-16
26. Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging 1997;18:351-57
27. Williams MM, Storandt M, Roe CM, et al. Progression of Alzheimer's disease as measured by Clinical Dementia Rating Sum of Boxes scores. Alzheimers Dement 2013;9(1 Suppl):S39-44
28. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993;43:2412-14
29. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984;141:1356-64
30. Rockwood K, Fay S, Gorman M, et al. The clinical meaningfulness of ADAS-Cog changes in Alzheimer's disease patients treated with donepezil in an open-label trial. BMC Neurol 2007;7:26
31. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98
32. Fitzmaurice GM, Laird NM, Ware JH. Applied Longitudinal Analysis. Hoboken, New Jersey: Wiley; 2011
33. Bernick C, Cummings J, Raman R, et al. Age and rate of cognitive decline in Alzheimer disease: implications for clinical trials. Arch Neurol 2012;69:901-05
34. Plassman BL, Langa KM, Fisher GG, et al. Prevalence of dementia in the United States: the aging, demographics, and memory study. Neuroepidemiology 2007;29:125-32
35. Corder EH, Ghebremedhin E, Taylor MG, et al. The biphasic relationship between regional brain senile plaque and neurofibrillary tangle distributions: modification by age, sex, and APOE polymorphism. Ann N Y Acad Sci 2004;1019:24-28
36. Yaffe K, Haan M, Byers A, et al. Estrogen use, APOE, and cognitive decline: evidence of gene-environment interaction. Neurology 2000;54:1949-54
37. Xu H, Gouras GK, Greenfield JP, et al. Estrogen reduces neuronal generation of Alzheimer beta-amyloid peptides. Nat Med 1998; 4:447-51
38. Prince JA, Zetterberg H, Andreasen N, et al. APOE epsilon4 allele is associated with reduced cerebrospinal fluid levels of Abeta42. Neurology 2004;62:2116-18
39. Kester MI, Blankenstein MA, Bouwman FH, et al. CSF biomarkers in Alzheimer's disease and controls: associations with APOE genotype are modified by age. J Alzheimers Dis 2009;16:601-07
40. Walker LC, Pahnke J, Madauss M, et al. Apolipoprotein E4 promotes the early deposition of Abeta42 and then Abeta40 in the elderly. Acta Neuropathol 2000;100:36-42
41. Koffie RM, Hashimoto T, Tai HC, et al. Apolipoprotein E4 effects in Alzheimer's disease are mediated by synaptotoxic oligomeric amy-loid- beta. Brain 2012;135:2155-68
42. DeKosky ST, Scheff SW. Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity. Ann Neurol 1990;27:457-64
43. Van Hoesen GW, Parvizi J, Chu CC. Orbitofrontal cortex pathology in Alzheimer's disease. Cereb Cortex 2000;10:243-51
44. Saunders AM. Apolipoprotein E and Alzheimer disease: an update on genetic and functional analyses. J Neuropathol Exp Neurol 2000;59:751-58
45. Growdon JH, Locascio JJ, Corkin S, et al. Apolipoprotein E genotype does not influence rates of cognitive decline in Alzheimer's disease. Neurology 1996;47:444-48
46. Cosentino S, Scarmeas N, Helzner E, et al. APOE epsilon 4 allele predicts faster cognitive decline in mild Alzheimer disease. Neurology 2008;70:1842-49
47. Juva K, Verkkoniemi A, Viramo P, et al. APOE epsilon4 does not predict mortality, cognitive decline, or dementia in the oldest old. Neurology 2000;54:412-15
48. Hyman BT. Amyloid-dependent and amyloid-independent stages of Alzheimer disease. Arch Neurol 2011;68:1062-64